UNITED STATES SECURITIES AND EXCHANGE COMMISSION July 11, 2016

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aviragen Therapeutics, Inc.

File No. 001-35285 -CF#33730

Aviragen Therapeutics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on April 26, 2016.

Based on representations by Aviragen Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1

through April 25, 2026

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary